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Combination therapyMany ovarian cancer cells express stress-relatedmolecule MICA/B on their surface that is recognized by Vγ2Vδ2
T cells through their NKG2D receptor, which is transmitted to downstream stress-signaling pathway. However, it
is yet to be established how Vγ2Vδ2 T cell-mediated recognition of MICA/B signal is transmitted to downstream
stress-relatedmolecules. Identifying targetedmolecules would be critical to develop a better therapy for ovarian
cancer cells. It is well established that ATM/ATR signal transduction pathways, which is modulated by DNA
damage, replication stress, and oxidative stress play central role in stress signaling pathway regulating cell
cycle checkpoint and apoptosis. We investigated whether ATM/ATR and its down stream molecules affect
Vγ2Vδ2 T cell-mediated cytotoxicity. Herein, we show that ATM/ATR pathway is modulated in ovarian cancer
cells in the presence of Vγ2Vδ2 T cells. Furthermore, downregulation of ATM pathway resulted downregulation
of MICA, and reduced Vγ2Vδ2 T cell-mediated cytotoxicity. Alternately, stimulating ATM pathway enhanced
expression of MICA, and sensitized ovarian cancer cells for cytotoxic lysis by Vγ2Vδ2 T cells. We further show
that combining currently approved chemotherapeutic drugs, which induced ATM signal transduction, along
with Vγ2Vδ2 T cells enhanced cytotoxicity of resistant ovarian cancer cells. These ﬁndings indicate that ATM/
ATR pathway plays an important role in tumor recognition, and drugs promoting ATM signaling pathway
might be considered as a combination therapy together with Vγ2Vδ2 T cells for effectively treating resistant
ovarian cancer cells.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Human innate immune system provides ﬁrst line of defense against
multiple viral or bacterial attacks, and provides critical surveillance
against oncogenic development. Evidences show that individuals with
primary immunodeﬁciency or induced immunosuppression during
organ or cell transplantation showed higher risk for tumor development
[1]. Alternately, impaired function of innate immune cells such as natu-
ral killer (NK) cells, subset ofαβ T cells, and γδ T cells leads to increased
susceptibility of the host for tumor growth [2,3]. Among these innate
immune cells, γδ T cells (Vγ2Vδ2 subset) are of particular interest due
to their dual role in the immune system for bridging the gap between
the innate and adaptive immunity, and have been demonstrated critical
anti-tumor activities [4–6]. Due to the robust metabolic activities
in tumor cells, speciﬁc antigens such as MHC class-I chain-relatede Ohio State University, 460W.
614 688 8711 (ofﬁce); fax:+1molecules MICA/B were typically found to be highly expressed in most
tumor cells compared to normal healthy cells [7]. These antigens were
speciﬁcally recognized by the Vγ2Vδ2 T cells and were proposed to
enhance the cytotoxic activity of Vγ2Vδ2 T cells towards a variety of
tumor cells [8–11]. The activating receptors, NKG2D, serves as one of
the most important receptors present in Vγ2Vδ2 T cells and mediate
the recognition process to eliminate the tumor cells. This NKG2D
molecule not only interacts to the receptor MICA/B, but also interacts
with molecules such as ULBPs [12].
Emerging T cell-based adaptive immunotherapy is under consider-
ation for various cancers as a therapeutic regimen [13]. In the adoptive
therapy, T cells are activated, expanded ex vivo and reinjected into the
patientswith tumors [14,15]. Adoptive T-cell therapy in renal cancer pa-
tients showed no adverse events, and 3 of 5 patients showed slower
tumor progression. Patients documented with a positive response
showed an increased number of Vγ2Vδ2 T cells in the peripheral
blood and a strong in vitro response to phosphoantigen stimulation
[14]. Various trials show promise for development of autologous
Vγ2Vδ2 T cell therapies in eligible patients. However, for ovarian
cancer, there is currently no effective immunotherapy. Interestingly,
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cell death, which is crucial for tumor eradication and long-term protec-
tion against relapse. Moreover, Vγ2Vδ2 T cells were recruited to the
tumor bed after immunogenic chemotherapy and appear to be contrib-
utors to the efﬁcacy of chemotherapy [16]. So, developing a combina-
tion therapy using chemotherapeutic reagent and Vγ2Vδ2 T cells will
be a valuable option to be tested.
The Vγ2Vδ2 T cells induce cytotoxicity in many ovarian tumor cells
via induction of apoptosis [17]. However, some of the ovarian tumor
cells evade the apoptosis process and became resistant towards
Vγ2Vδ2 T cell-mediated cytotoxicity. These resistant cell lines (such as
A2780) showed slower proliferation compared to the sensitive cell
line (such as OV4); interestingly, we found that the resistant cell line
has reduced expression of MICA [17]. We proposed that the tumor
cells may evade the Vγ2Vδ2 T cell cytotoxicity by down-regulating
their MICA expression and at the same time enter into a dormancy
stage, in which their proliferation was slowed down. In the current
study, we further investigated the molecular mechanisms involved in
the immune escape process. It has been shown that genotoxic stress
or inhibitors of DNA-replication could up-regulate the expression of
NKG2D ligand through activation of ATM (ataxia telangiectasia mutat-
ed) and ATR (ATM- and Rad3-related) protein kinase pathway in
human ﬁbroblast and in mouse tumor cell lines, which led to enhance
cytotoxic lysis by NK cells [18,19]. ATM and ATR are activated in re-
sponse to DNA damage, oxidative stress, and replication stress resulting
in apoptosis or cell cycle arrest. After activation ATM phosphorylates
Chk2, and ATR phosphorylates Chk1 to start a cascade of downstream
signaling events [20]. Activated Chk1 and Chk2 phosphorylate Cdc25
phosphatases, to inhibit their function, and the cells delay progression
though the cell cycle [20]. After activation ATR and ATM also phosphor-
ylate H2A variant H2AX at Ser-139 (γH2AX) at the damage sites, or
where chromosomes are fragmented by oxidative stress [21].
TheγH2AXhas been used as amarker for DNAdamage, oxidative stress,
and replication stress. Itwas also shown that inhibition of ATMpathway
by using synthetic inhibitor such as KU-55933 suppressed cell prolifer-
ation and induced apoptosis [22]. In this study, we examined whether
the ATM and ATR protein kinases play a role in Vγ2Vδ2 T cell-mediated
recognition of ovarian cancer cells. We found that treatment of ovarian
cancer cells with Vγ2Vδ2 T cells results in down regulation of ATR and
ATMsignal transduction in resistant cells, but remain unchanged in sen-
sitive cells. When we treated the cells with Vγ2Vδ2 T cells along with
drugs activating ATMpathway, it resulted a signiﬁcant increase in cyto-
toxicity of tumor cells. Thus, ATM–Chk2 signal transduction plays a crit-
ical role in regulating tumor survival in ovarian cancer upon Vγ2Vδ2 T
cell treatment.
2. Materials and methods
2.1. Derivation of Vγ2Vδ2 T cells
Human peripheral blood was collected (30 ml) from adult healthy
donors after obtaining the IRB approval from the Ohio State University
Medical Center and obtaining written consents from donors. The ethic
committee has also approved the procedure and records are saved in
the laboratory. Freshly collected blood was processed to isolate periph-
eral blood mononuclear cells (PBMC) following the similar protocol
published earlier [10,11]. In brief, the peripheral blood was diluted
twice with phosphate buffered saline (PBS, pH 7.4) and carefully lay-
ered over 10 ml of Ficoll-Paque Plus solution (GE Healthcare, Uppsala,
Sweden). After 30 min of centrifugation in a swinging bucket rotor at
1400 rpm at room temp (24 °C); the upper layer was aspirated out
and the mononuclear cell layer (buffy coat) was collected. Buffy
coat was washed three times with PBS to remove platelets. One
million of PBMC in each well was stimulated with 10 μM risedronate
in a 24-well plate using 1 ml RPMI 1640 supplemented with 10% fetal
bovine serum (FBS, HyClone Lab Inc., Logan, UT), 2 mM glutamine,1 nM β-mercapto ethanol, 1 nM HEPES, and 100 IU of penicillin and
streptomycin at 37 °C incubator. Recombinant IL-2, 0.5 nM (PeproTech
Inc. Rocky Hill, NJ) was added to the culture on days 3 and 7. Cells were
split after day 10 using the complete RPMI 1640 media supplemented
with 0.5 nM rIL-2. Flowcytometric (FACS) analysis was performed
(using a FACS Calibur machine, BD Biosciences, CA) at day 14, to evalu-
ate phenotype of the expanded cell. FACS analysis data revealed that
99.8% of the expanded cells were CD3+, and 89.5% of them were
Vδ2+. Cells were used between 15 and 19 days of initial culture for
further experiments discussed below.
2.2. Ovarian cancer cells and chemicals
The ovarian cancer cells (A2780 and OV4; purchased from ATCC, VA,
and used within six months of receipt) were cultured in 10 cm or 6 cm
culture dishes in DMEM media supplemented with 10% FBS and
antibiotics.Chemicals/drugs that were used in this study include
H4073 (5 μM, kind gift from Prof. Periannan Kuppusamy, Columbus,
OH), etoposide (500 μM, MP Biomedical LLC, Santa Ana, CA), KU55933
(10 μM, Selleck Chemicals, Houston, TX), caffeine (5 mM, kind gift
from Prof. Jeff Parvin, Columbus, OH), Neocarzinostatin, NCS
(500 ng/ml, Cat# N9162, Sigma, St. Louis, MO, USA).
2.3. Protein analyses
Total protein analysis was performed using standard western blot
(WB) technology. Half a million of tumor cells (A2780 or OV4) were
pre-seeded in 6 cm Petri dish for 10 h before adding Vγ2Vδ2 T cells.
Control plates were also plated at the same time to maintain equal cell
numbers. We did not observe any signiﬁcant change on cell numbers
after 10 h of pre-seeding. Fresh medium (RPMI for A2780 and DMEM
for OV4) containing 10% FBS were replaced to the culture plates. Two
and a half million of Vγ2Vδ2 T cells were added to the tumor cells to
make a ratio of C:T= 1:5 (where ever applicable). Protein was isolated
after 4 and 24 h of addition of Vγ2Vδ2 T cells. Before isolation of total
protein, Vγ2Vδ2 T cells were gently removed by washing with 1×
PBS. Forty to sixty microgram of total protein from each sample was
used for a single WB analysis. Various antibodies have been used for
WB, such as ATM, phosphorylated (p) ATM, ATR, pATR, pCHK1,
pCHK2, H2AX, and γH2AX to detect their level of expressions on
tumor cells at various time points of co-culture with Vγ2Vδ2 T cells.
2.4. ATM silencing
ATMshRNAwas obtained from SigmaAldrich Inc. (ATM shRNAplas-
mid from bacterial glycerol stock TRCN0000039949 (deﬁned as #1) and
TRCN0000039950 (deﬁned as #2) and an irrelevant negative control
shRNA plasmid). Transfection with various RNAs in A2780 cells was
conducted using Lipofectamine™ 2000 transfection reagents
(Invitrogen) according to the manufacturer's instruction and earlier
published methods [23].
2.5. Cytotoxicity assays
The cytotoxicity assay was performed using the LIVE/DEAD® Cell-
Mediated Cytotoxicity Kit (Invitrogen Inc.) and repeated by 3–6 times
for each condition. Protocol was followed as suggested with little mod-
iﬁcation. Five hundred thousand of ovarian cancer cells (A2780) were
pre-seeded on a 6 cm dish for 8 h. Cells were then stained with
DiOC18 (7.5 μM) for 3 h. After staining, DiOC18 was washed by three
times with 1× PBS, then, 1:10 ratio of Vγ2Vδ2 T cells were added in
combination of various treatment molecules including H4073,
etoposide, KU55933, caffeine, and NCS. After 24 h, ﬂoating cells were
collected and adhesion cells were collected by adding non-enzymatic
cell dissociation buffer andmixedwith correspondingﬂoating cells. Col-
lected cells were then stainedwith Propidium Iodide (PI 37.5 μM). After
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were incubated at 37 °C for 30 min. After staining with PI, the cells
were evaluated immediately by ﬂowcytometry for the cytotoxicity ef-
fect of Vγ2Vδ2 T cells. Upper-gated cells are PI stained dead cancer
cells and lower gated cells are PI stain negative live cancer cells that
are DiOC18 positive.
2.6. MitoSox™ Red staining
MitoSOX™ Red mitochondrial superoxide indicator was purchased
from Invitrogen. The concentrations were maintained as 0.19 mg/ml
to stain 500 K cells. In brief, 500 K A2780 tumor cells were pre-seeded
in 6 cm Petri-dish for 8 h in complete RPMI medium. After pre-
seeding, medium was replaced with fresh complete RPMI. Tumor cells
were co-culturedwith Vγ2Vδ2 T cells at 1:10 ratio under different treat-
ment conditions as indicated before including H4073, etoposide,
KU55933, caffeine, and NCS. After 24 h cells were collected after wash-
ing with medium. Very few adherent cancer cells were washed away
when we removed non-adherent Vγ2Vδ2 T cells from co-culture.
After all cells were collected, staining reagent was added using concen-
tration indicated before. After 10min of staining, cells werewashed one
time with 1× PBS and processed immediately for ﬂowcytometric
analysis. Adherent cells were collected after adding non-enzymatic
cell dissociation buffer (Sigma) and collected after spin down with PBS.
2.7. Flowcytometry
A2780 tumor cells were pre-seeded in 6 cmPetri dish for 8 h in com-
plete RPMI medium. After pre-seeding, medium was replaced with
fresh complete medium. Tumor cells were co-cultured with Vγ2Vδ2 T
cells at 1:10 ratio under various treatment conditions as indicated be-
fore including H4073, etoposide, KU55933, caffeine, and NCS. After
24 h, all cells were collected after spinning downwith existingmedium.
Adherent cells were collected after adding non-enzymatic cell dissocia-
tion buffer (Sigma) and collected after spin down with PBS. PE-
conjugated MICA/B and PE-conjugated IgG antibodies were added to
the different samples. After 45 min incubation in ice, cells were washed
once with PBS and processed for ﬂowcytometry.
2.8. Immunoﬂuorescence staining
Immunoﬂuorescence staining was performed to analyze protein ex-
pressions after the treatmentwith various relevant chemicals and drugs
in the presence or absence of Vγ2Vδ2 T cells. In brief, half a million of
A2780 cancer cells (C) were pre-seeded in 6 cm Petri dish 10 h before
adding Vγ2Vδ2 T (T) cells. Fresh RPMI medium containing 10% FBS
was replaced to the culture plates. Vγ2Vδ2 T cells were added to the
tumor cells to make a ratio of C:T = 1:10. Optimum concentration of
chemical/drugswas added such as H4073, etoposide, KU55933, caffeine
or NCS before adding Vγ2Vδ2 T cells. Cells were stained after 24 h of co-
culture. Brieﬂy, cells were washed with 1× PBS for three times gently.
Cells were ﬁxed with 4% paraformaldehyde for 30 min and perme-
abilized with 0.1% triton-X-100 for 30 min. After blocking, cells were
stained by various antibodies such as ATM, pATM, ATR, pATR, CHK1,
pCHK1, CHK2, pCHK2, H2AX or γH2AX to detect their level of expres-
sion on tumor cells.
3. Results
3.1. Differential expression of ATM/ATR signaling pathway molecules in
ovarian cancer cells upon Vγ2Vδ2 T cell induction
Many epithelial cancer cells express stress-relatedmolecules such as
MICA/B on their surface and Vγ2Vδ2 T cells recognize those molecules
through NKG2D receptor molecules expressed on them. However, it is
yet to be investigated how Vγ2Vδ2 T cell-mediated recognition ofMICA/B signal is transmitted to downstream stress-related molecules,
and the molecular mechanism of this signal transduction pathway. Ex-
ploring this pathway would be critical to develop better therapies for
ovarian cancer cells. Upon DNA damage, replication stress, and oxida-
tive stress, ATM/ATR signal transduction pathway plays a central role
in regulating cell cycle checkpoint and apoptosis [20]. To identify the
stress-related downstream signaling pathways in response to Vγ2Vδ2
T cells, we have used OV4 (sensitive), and A2780 (resistant) ovarian
cancer cell lines [17]. Downstream factors of ATM/ATR pathways and
their activation by phosphorylation were analyzed using Western blot
(Fig. 1). Western blot analysis revealed that there was no signiﬁcant
change in the total protein levels of ATM and ATR at both 4 h and 24 h
time points, however pATM and pATR levels were enhanced at 24 h
when co-cultured with Vγ2Vδ2 T cells in OV4 cells (Fig. 1, left panel).
In contrast, H2AX is signiﬁcantly phosphorylated in both 4 h and 24 h
when co-cultured with Vγ2Vδ2 T cells, suggesting a general stress-
and DNA damage-mediated phosphorylation of H2AX. Besides ATR
and ATM, H2AX is also phosphorylated by DNA-pK. Therefore, there
might be some contribution of DNA-pK in H2AX phosphorylation
upon Vγ2Vδ2 T cell induction. A2780 resistant cells did not show any
signiﬁcant difference in total ATM and ATR levels when co-cultured
with Vγ2Vδ2 T cells. However, the levels of pATM and pATR were
downregulated when compared to total ATM and ATR, upon co-
culture with Vγ2Vδ2 T cells, in both 4 h and 24 h time points (Fig. 1,
right panel). Accordingly, ATM substrate Chk2 phosphorylation
(pChk2) and ATR substrate Chk1 (pChk1) were also downregulated at
4 h and 24 h upon Vγ2Vδ2 T cell induction. This data showed that
ATM-Chk2 and ATR-Chk1 signaling pathways are downregulated
upon Vγ2Vδ2 T cell induction. We noticed that γH2AX is substantially
downregulated at 24 h, but this is not evident at 4 h, further indicating
that H2AX phosphorylation is inﬂuenced by different kinases besides
ATR andATM. Based on these preliminary observations, we hypothesize
that downregulation of ATR-Chk1 and ATM-Chk2 pathways might play
a critical role in promoting the resistance of A2780 towards Vγ2Vδ2 T
cell-mediated cytotoxicity.
3.2. Induction of ATM enhances Vγ2Vδ2 T cell-mediated cytotoxicity and
speciﬁc inhibitors of ATM reduce cytotoxicity
It has been shown that genotoxic stress or inhibitors of DNA-
replication could up-regulate the expression of NKG2D ligand through
activation of ATMand ATR protein kinase pathways in human ﬁbroblast
and in mouse tumor cell lines, which led to enhanced cytotoxic lysis by
NK cells [18,19]. The reduction of ATMactivation upon Vγ2Vδ2 T cell in-
duction in resistant ovarian cancer cells (A2780), suggests that some-
how regulatory pathways involved in ATM activation are affected in
this resistant cell line. Considering this possibility, we hypothesize that
upregulation or induction of ATM would enhance Vγ2Vδ2 T cell-medi-
ated cytotoxicity of these resistant cells. We next tested this hypothesis
by doing following experiments. We selected three different chemicals
or drugs (NCS, etoposide, and H4073), known to inﬂuence ATM signal-
ing pathway, and combined themwith Vγ2Vδ2 T cells to determine the
cytotoxicity in combination treatment. NCS is a macromolecular chro-
moprotein enediyne antibiotic, which leads to double-strand DNA
cleavage [24]. Etoposide results in immediate ATM activation by
inhibiting topoisomerase and thus DNA synthesis [25]. Studies implicat-
ed that etoposide could be used as a second-line of therapy both for
platinum-resistant and platinum-sensitive ovarian cancer patients
[26–28]. The H4073, a curcumin analog and food additive has demon-
strated anti-tumor activity, but does not induce ATM [29]. We have op-
timized both the dose of molecules and Vγ2Vδ2 T cell concentration to
demonstrate the speciﬁc effects on ovarian cancer cells. By using live/
dead ﬂowcytometric analysis study, we show that all three molecules
have cytotoxic effect to the tumor cells and that the effect could be sig-
niﬁcantly enhanced by using application of Vγ2Vδ2 T cells (Fig. 2). The
values (±SEM) for the level of cytotoxicity are as follows: A2780=3.45
Fig. 1. Levels of ATR and ATM signaling pathwaymolecules in ovarian cancer cells. A sensitive (OV4) and a resistant (A2780) ovarian cancer cells were co-culturedwith ex-vivo-expanded
Vγ2Vδ2 T cells at a ratio of cancer: Vγ2Vδ2 T cells= 1:5, and the cancer cellswere harvested at 4 h and 24 h time points to isolate total protein after gentle removal of Vγ2Vδ2 T cells. Total
proteins were subjected to the Western blot analysis using relevant Abs as stated.
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24.60 ± 4.29; etoposide = 7.50 ± 0.18; etoposide + T = 39.77 ±
1.45; H4073 = 25.69 ± 3.78; H4073 + T = 36.72 ± 8.12; caffeine
= 4.80 ± 0.47; caffeine + T = 7.64 ± 0.34; KU3393 = 5.17 ± 0.44;
and KU3393 + T = 6.04 ± 0.56.
In the current experimental setting, the optimum dose of NCS and
etoposide was not able to induce remarkable lysis of tumor cells; how-
ever, when Vγ2Vδ2 T cells were added, the cytotoxicity effect wasFig. 2. ATM-inducing molecules enhance Vγ2Vδ2 T cell-mediated cytotoxic lysis of ovarian can
presence of NCS, etoposide, and H4073 molecules using a LIVE/DEAD cell-mediated viability/c
and methods section. Upper-gated cells are PI stained dead cancer cells and lower gated cells asigniﬁcantly boosted indicating synergistic effect of NCS and etoposide
with Vγ2Vδ2 T cell treatment. In contrast, H4073 was shown to be
able to induce strong apoptosis to the A2780 cells; however, in combi-
nation with Vγ2Vδ2 T cells, no synergistic effect of apoptosis was ob-
served. Our data support a possibility of the involvement of the ATM
pathway in enhanced cytotoxicity of resistant ovarian cells. To further
assess this possibility, we used two ATM inhibitors such as caffeine
(general inhibitor) and KU55933 (speciﬁc inhibitor) to abrogate orcer cells. Cytotoxicity of Vγ2Vδ2 T cells towards ovarian cancer cells was performed in the
ytotoxicity kit and ﬂowcytometric analysis following protocol mentioned in the Materials
re PI-stain negative live cancer cells that are DiOC18 positive.
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were subjected to various treatments to optimize the synergistic
effect of ATM on Vγ2Vδ2 T cell-mediated cytotoxicity in a live/dead
ﬂowcytometric assays (Fig. 3). Both caffeine and KU55933 were able
to abolish the cytotoxic effect of Vγ2Vδ2 T cells. There is no signiﬁcant
difference in the inhibitory effect between caffeine and KU55933, indi-
cating a possible high dependency of Vγ2Vδ2 T cells on the ATM path-
way. In contrast, when ATM stimulator NCS was added, the cytotoxic
effect of Vγ2Vδ2 T cells was boosted by two-fold. Interestingly, caffeine
or KU55933 (data not shown) alone was able to reduce the boost,
indicating that ATM indeed plays an important role in regulating the ap-
optotic response induced by Vγ2Vδ2 T cells in A2780 cells. However,
there was no signiﬁcant inhibitory effect of Vγ2Vδ2 T cell-mediated cy-
totoxicity on tumor cells from caffeine in the presence of H4073, which
does not induce ATM, conﬁrming the caffeine and KU55933 effect was
ATM speciﬁc.3.3. Oxidative stress and ROS production in mitochondria of cancer cells
upon induction of Vγ2Vδ2 T cells
It has been shown that ATMsignaling pathway is activatedupon cer-
tain levels of reactive oxygen species (ROS) induction [30]. Therefore,
we next investigated whether ROS was the major contributor in the
tumor cell lysis. ROS production was evaluated in tumor cells using
MitoRed staining technique and ﬂowcytometric evaluation in various
treatment conditions. ATM inducers or ATM inhibitors alone couldFig. 3.ATM inhibition reduces cytotoxic lysis of ovarian cancer cells byVγ2Vδ2 T cells. TheVγ2V
etoposide, and H4073 molecules along with ATM inhibitors. Flowcytometric analysis was perf
Upper-gated cells are PI stained dead cancer cells and lower gated cells are PI-stain negative ligenerate ROS production in the mitochondria of tumor cells. Even
though Vγ2Vδ2 T cells were able to increase the ROS production
compared with control tumor cells, the addition of NCS or etoposide
didn't show any signiﬁcant enhancement of ROS production (data not
shown). Treating the cells with caffeine or KU55933 has showed slight
decrease in ROS production compared to controls. However, H4073 sig-
niﬁcantly increased the ROS production in the presence of Vγ2Vδ2 T
cells indicating that ROS production might play an important role in
H4073 induced apoptosis (data not shown). However, we predict that
in our experimental condition, overall ROS production doesn't seem to
play an important role in the synergistic effect of Vγ2Vδ2 T cells and
ATM inducer-induced cytolysis.3.4. Downstream signalingmolecules of ATM/ATR pathway involved in lysis
of tumor cells in combination therapy
Immunocytochemical analysis was performed to better understand
the modulation of the stress-related signaling molecules in tumor cells
in the presence of ATM stimulatory chemicals (NCS and etoposide)
and Vγ2Vδ2 T cells after 24 h of co-culture (Fig. 4). As expected, NCS
and etoposide increased the expression of pATM and pATR, which
leads to increased susceptibility towards tumor cells (Fig. 4AB). Addi-
tionally, the pChk2 and γH2AX levels also showed increase in their
levels upon combination treatment (Fig. 4DE). No signiﬁcant change
was observed on pCHK1 level, suggesting that ATR–Chk1 pathway
might not be the predominant pathway activated when treated withδ2 T cell-mediated cytotoxicity of ovarian cancer cellswas evaluated in thepresenceofNCS,
ormed to evaluate cytotoxicity using a LIVE/DEAD cell-mediated viability/cytotoxicity kit.
ve cancer cells that are DiOC18 positive.
Fig. 4. Expression of ATM/ATR pathway molecules in the presence of Vγ2Vδ2 T cells and ATM inducing factor. Ovarian cancer cells were co-cultured with Vγ2Vδ2 T cells for 24 h at 1:10
ratios alongwith ATM inducing factor (NCS), and various ATM/ATR pathwaymoleculeswere assessedusing immunocytochemical techniques (A–E). F. Level of activation (phosphorylated
form) in ATM/ATR and their substrate (ChK2/Chk1) molecules in A2780 cells with NCS, H4073, and etoposide stimulus or with ATM-inhibitors (caffeine or Ku55933).
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ern blot analysis. Our results also show that NCS, and etoposide induced
activation (phosphorylation) of ATM/ATR and their substrate Chk2/
Chk1 respectively (Fig. 4F). Conversely, ATM inhibitors (caffeine, and
KU55933) reduce expressions of the ATM/ATR and their substrate
Chk2/Chk1 molecules (Fig. 4F).
3.5. ATM stimulator induces surface expression of MICA
To understand the contributory role of ATM signaling pathway, and
its cross-talk with already known molecules activated by Vγ2Vδ2 T
cells, nextwe examined the levels ofMICA expression on ovarian cancer
cells. We investigated whether the synergistic cytotoxicity by ATM
inducer and Vγ2Vδ2 T cell treatment, is mediated by modulation of
MICA expression. Therefore, we tested whether ATM inducer has any
effect on MICA expression on the tumor cells. Flowcytometric analysis
revealed that NCS and etoposide, inducers of ATM, also enhanced
surface expression of MICA in A2780 cells. As such these cells reduced
surface expression of MICA in the presence of Vγ2Vδ2 T cells and be-
come resistant to the cytotoxic lysis [17]. However, in the presence of
ATM inducers these cells could not reduce surface expression of MICAwhen Vγ2Vδ2 T cells were added; instead they increased the MICA ex-
pression (Fig. 5A). These data showed that ATM inducers directly pro-
mote MICA expression, which then enhance the cytotoxic effect in
resistant tumor cells when ATM inducers and Vγ2Vδ2 T cells were
combined.
If this is true, then the ATM inhibitors should show an effect onMICA
expression. In the absence of Vγ2Vδ2 T cells, inhibiting ATM by caffeine
or KU55933 leads to down-regulation in surface expression of MICA on
A2780 cells (Fig. 5B). However, stimulating ATM using NCS leads to an
up-regulation of surface expression of MICA. These results indicated
that activated ATM in A2780 cells leads to positive expression of
MICA, which was able to boost the recognition of tumor cells by
Vγ2Vδ2 T cells. This is consistent with the ﬁnding in our previous pub-
lished paper, where we showed that the MICA down-regulation played
a critical role in A2780 cell's resistance towards Vγ2Vδ2 T cell cytotox-
icity compared to OV4 cell line [17]. Molecules such as etoposide were
also able to promote MICA expression, which might follow similar
mechanisms to NCS.When co-cultured with Vγ2Vδ2 T cells similar pat-
tern was also observed in NCS and etoposide (Fig. 5A). H4073 was able
to slightly increase the expression of MICA compared to no drug treat-
ment in the context of Vγ2Vδ2 T cells; even though the effect is much
Fig. 5. ATM-inducingmolecule enhances surface expression of MICA in ovarian cancer cells and ATM-inhibitor reduces it. A. Ovarian cancer cells were co-culturedwith Vγ2Vδ2 T cells for
24 h at 1:10 ratios in the presence or absence of ATM-inducing factors (NCS or etoposide) and assessed for surface expression of MICA level using ﬂowcytometry. Appropriate isotype Ab
was used as a control. B. The surface expression of MICA molecule on ovarian cancer cells was also assessed by ﬂowcytometry in the presence or absence of Vγ2Vδ2 T cells and ATM-
inhibiting factors (caffeine or Ku55933). C. ATMknock down inA2780 cellswas evaluated byWBmethods. Upper panel shows the level of ATMand lower panel shows the level of internal
control GAPDH. D. Flowcytometric analysis for MICA. ATM knocked down cells were subjected to ﬂowcytometric analysis for surface expression of MICA molecule.
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synergistic effect observed in H4073 + Vγ2Vδ2 T cells. This result
emphasize that MICA regulation by ATM signaling pathway may play
a critical role in the resistance of A2780 towards Vγ2Vδ2 T cell treat-
ment, and stimulating ATM might be important in sensitizing A2780
cell line by up-regulating MICA expression.
To further conﬁrm the direct involvement of ATM pathway in regu-
lation of MICAmolecule in ovarian cancer cells, we have knocked down
ATM in A2780 cells using shRNA-mediated knock down approach. ATM
knock down was evaluated by WB methods and found that one of the
ATM shRNAs (#2) is more effective in knocking down of ATM than
the other (#1) (Fig. 5C). To investigate the effect of ATM knockdown
on surface expression of MICA on A2780 cells, ﬂowcytometric analysis
was performed for MICA. We found that knock down of ATM by using
ATM shRNA (#2) in A2780 cells also downregulated MICA expression
in ovarian cancer cells (Fig. 5D).
4. Discussion
The cytotoxic T cells, particularly Vγ2Vδ2 T cells, are important for
the consideration of immunotherapy due to the fact that they: 1) recog-
nize transformed cells independent of antigen processing or presenta-
tion by classical MHC molecules, and 2) possess the strong anti-tumoreffector functions. It has been shown that aminobisphosphonates, a
class of drugs used as adjuvant cancer therapy for the treatment of
malignant osteolytic bone disease, have effects of potently activating
the anti-tumor effector functions of human peripheral Vγ2Vδ2 T cells.
Despite the relative complexity of immunotherapy, such treatment
may have an important role, in conjunction with other therapies in
the treatment of cancer refractory to conventional treatments alone.
Clinical studies have recently shown that adding immunotherapy to
chemotherapy has survival beneﬁts in comparison to chemotherapy
alone [31]. Moreover, chemotherapeutic agents can sensitize tumors
to immune cell-mediated killing [32–34]. For instance, some can in-
crease sensitivity of tumor cells via up-regulation of death receptors
DR5 and Fas, ligands to TRAIL and FasL respectively [6]. Similarly,
Vγ2Vδ2 T cells could be selectively activated by naturally occurring
phosphoantigens, which are accumulated in remarkably higher amount
in stressed cells, or synthetic drugs offer new avenues for the develop-
ment of effective T cell-based immunotherapies. Currently, several pro-
tocols based on the in vivo activation of Vγ2Vδ2 T cells with
phosphoantigens or aminobisphosphonates, or the adoptive transfer
of in vitro expanded Vγ2Vδ2 T cells are in development for the treat-
ment of several tumors [6].
Several mechanisms were identiﬁed in tumor cells by which they
defend against Vγ2Vδ2 T cells, including inhibiting recruitment of
Fig. 6. Interaction of Vγ2Vδ2 T cells and ovarian cancer cells. Schematics showing
involvement of ATM pathway in Vγ2Vδ2 T cell-mediated cytotoxicity.
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cules, promoting immunosuppressive activities such as blocking den-
dritic cell maturation and promote regulatory T cells [35]. All these
studies do not address, the molecular signaling pathways activated in
tumor cells uponVγ2Vδ2 T cell induction.We anticipate that identifying
Vγ2Vδ2 T cell-mediated signaling pathways, and establishing the mo-
lecular mechanism of their function would help develop a more effec-
tive Vγ2Vδ2 T cell-mediated therapy. The Vγ2Vδ2 T cells induce
oxidative stress, which upregulates NKG2D ligand MICA [36–38].
Furthermore, MICA upregulation transmits its signal through the
phosphoinositide 3-kinase (PI3K) related kinase pathway [39]. The
PI3K/AKT/mTOR pathway can become abnormally activated in many
human tumors and thereby contributes to cell growth, cell proliferation,
and angiogenesis [40–42].We previously shown that ovarian tumor cell
lysis due to Vγ2Vδ2 T cell induction were mediated via AKT and ERK
pathway [17]. Thus, our results showed an oxidative stress-mediated
regulation of PI3K/AKT/mTOR pathway [43]. Importantly, it has been
shown that ATM is activated by phosphorylation upon oxidative stress,
and results in DNA damage response [21,44,45]. Oxidative stress results
in DNA single- and double-strand breaks, DNA–DNA and DNA–protein
cross links, and basemodiﬁcations, resulting in activation of ATMkinase
and its downstream signaling pathway. This damage response then ac-
tivates DNA repair, cell cycle checkpoint, changes in gene expression
proﬁles, and apoptosis [21,46]. Even though a link between NKG2D li-
gand activation and ATM damage response pathway has been implicat-
ed [47], whether ATM signal transduction is directly modulated upon
Vγ2Vδ2 T cell induction has not been established.
Our results indicated that in sensitive ovarian tumor cells, ATM and
ATR phosphorylation is enhanced (Fig. 1, left panel). Interestingly, in re-
sistant cells ATM–Chk2pathway is downregulated upon the recognition
of Vγ2Vδ2 T cells (Fig. 1, right panel), which resulted downregulation of
MICA and subsequent reduction of cytotoxicity and cell death. Our ob-
servation of downregulation of ATM and its substrates upon Vγ2Vδ2 T
cell induction is striking and led us to do the experiments usingATMen-
hancer and inhibitors.We observed that ATM-inducing drugs were able
to stimulate ATM level, which promotes cytotoxicity. On the other hand,
when we inhibited ATM signaling pathway by using ATM-speciﬁc in-
hibitors, it reduced the cytotoxic lysis of resistant cells after Vγ2Vδ2 T
cell induction. Thus, both ATM enhancers and inhibitors showed that
ATM–Chk2 signaling pathway plays a critical role in enhancing the sus-
ceptibility of tumor cells against Vγ2Vδ2 T cells. We investigated the
mechanism further, and revealed the cross-talk between the MICA
and ATM pathway by examining the changes in the MICA expression
level upon using ATM enhancers and inhibitors. We revealed that
MICA expression is upregulated when ATM signaling pathway is upreg-
ulated and MICA expression is downregulated when ATM signaling is
downregulated. These data support a direct cross-talk between ATM
pathway and MICA regulation. At this point, we do not know how
ATM inﬂuencesMICA regulation, but it shows that ATM signal transduc-
tions are directly linked to MICA regulation and cytotoxicity to Vγ2Vδ2
T cells (Figs. 2, 3 & 5). This direct link between ATM andMICA is further
conﬁrmed by using ATM knock down experiments (Fig. 5). It is highly
likely that ATM upregulation might inﬂuence the apoptosis pathway,
as it has been shown that ATM can promote apoptosis [48–50]. It will
be highly interesting to elucidate further signaling mechanisms in-
volved in the process of sensitization, which will be greatly helpful to
develop improved combination therapies for ovarian cancer.
Our results clearly demonstrate that inhibition of ATM pathway ac-
tivation results in resistance to Vγ2Vδ2 T cell-mediated cell death.
Therefore, enhancing ATM activation along with Vγ2Vδ2 T cell treat-
ment would promote the cytotoxicity of resistant ovarian cancer cells.
To our knowledge, this is the ﬁrst report of direct cross-talk of ATM sig-
naling and Vγ2Vδ2 T cell treatment. The molecular mechanism of the
inhibition of ATM pathway upon Vγ2Vδ2 T cell-mediated induction is
not clear yet, but it is obvious that ATM activation is affected by inhibi-
tion of its phosphorylation. Taken together, we propose that ovariancancer cells inhibit ATM signaling pathway upon Vγ2Vδ2 T cell treat-
ment, which in turn inhibit MICA surface expression, and reduce the cy-
totoxicity, resulting in resistance (Fig. 6). This also supports the
mechanism that Vγ2Vδ2 T cells induce cytotoxicity throughATMsignal-
ing pathway. Based on our results, for the ﬁrst time we tested a new
combination therapy where drugs like etoposide or NCS could be con-
sidered as a combination therapeutic regimens in conjunction with
Vγ2Vδ2 T cell-mediated immunotherapy for the treatment of ovarian
cancers. Moreover, if CD8+ αβ T cells and NK cells function similar to
the Vγ2Vδ2 T cells, then this combination therapywould be used to en-
hance cytotoxicity for these treatments. As resistance to chemotherapy
is challenging in ovarian cancer and many other cancer types, we be-
lieve that this new therapeutic approach would highly beneﬁt not
only ovarian cancers, but also other cancer types.
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